Analysts Viewpoint
Analyzing Allogene Therapeutics Inc (ALLO) After Recent Trading Activity
In a filing, Allogene Therapeutics Inc revealed its Director MESSEMER DEBORAH M. acquired Company’s shares for reported $52391.0 on Jun
Menu
In a filing, Allogene Therapeutics Inc revealed its Director MESSEMER DEBORAH M. acquired Company’s shares for reported $52391.0 on Jun
Allogene Therapeutics Inc’s recent filing unveils that its SVP, Finance Yoshiyama Annie unloaded Company’s shares for reported $13537.0 on Apr
Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its
Allogene Therapeutics, Inc. (ALLO), a clinical-stage immuno-oncology company, has dipped 32.73% and hence, ALLO stock was trading at $16.40 when